CardiaTec Biosciences, an AI drug target discovery company specialising in cardiovascular disease, has secured a £1.4 million pre-seed investment led by Laidlaw Scholars Ventures and APEX Ventures.
Cardiovascular diseases have persisted as the world’s leading global cause of death since the 1980s. Yet, despite the rising number of deaths, cardiovascular investment and therapeutic innovation are immensely dwarfed when compared to fields such as oncology and neurodegenerative diseases.
CardiaTec is developing a target discovery platform leveraging AI to make sense of large-scale multiomic cardiovascular data. As opposed to conventional singular omic analysis, CardiaTec’s proprietary platform unravels relationships that span across every level of biology, from gene variation, methylation and expression to their connection to proteomic and metabolomic functions to best understand disease development.
The Cambridge company was co-founded by Raphael Peralta (CEO), Thelma Zablocki (COO) and Dr. Namshik Han (CTO).
Peralta and Zablocki are graduates of the University of Cambridge MPhil in Bioscience Enterprise, while Dr Han is a world-leading academic in AI applications for target and drug discovery who holds positions at the University of Cambridge as Head of AI at the Milner Therapeutics Institute and Associate Faculty of the Cambridge Centre for AI in Medicine.
“We strongly believe, after several decades of stagnated investment and innovation, cardiovascular disease is re-emerging with newfound interest, driven not only by the increasing requirements to fulfil the unmet need as it persists as the world-leading cause of death, but in the application of AI in being able to drive new and meaningful insights to help meet patients needs,” said Peralta.
“Therefore, CardiaTec finds itself incredibly well placed to help drive innovation forwards within this space, now supported by a great syndicate of investors.”
MedTech 50 – UK’s most innovative medical technology creators for 2021